Alkermes Plc (ALKS)
29.52
+0.22
(+0.77%)
USD |
NASDAQ |
Dec 05, 16:00
29.52
0.00 (0.00%)
After-Hours: 17:35
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.875B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -5.67% |
| Valuation | |
| PE Ratio | 14.61 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.261 |
| Price to Book Value | 2.812 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0413 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 77.21% |
Profile
| Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland. |
| URL | http://www.alkermes.com |
| Investor Relations URL | https://investor.alkermes.com |
| HQ State/Province | Dublin |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 11, 2026 (est.) |
| Last Earnings Release | Oct. 28, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland. |
| URL | http://www.alkermes.com |
| Investor Relations URL | https://investor.alkermes.com |
| HQ State/Province | Dublin |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 11, 2026 (est.) |
| Last Earnings Release | Oct. 28, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |